Get the Stockscreener App
17.85
9.44%
1.54
After Hours:
17.80
-0.05
-0.28%
Erasca Inc stock is traded at $17.85, with a volume of 5.46M.
It is up +9.44% in the last 24 hours and up +31.06% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
See More
Previous Close:
$16.31
Open:
$16.248
24h Volume:
5.46M
Relative Volume:
0.92
Market Cap:
$5.55B
Revenue:
-
Net Income/Loss:
$-124.55M
P/E Ratio:
-40.63
EPS:
-0.4393
Net Cash Flow:
$-95.58M
1W Performance:
+4.63%
1M Performance:
+31.06%
6M Performance:
+640.66%
1Y Performance:
+1,340%
1-Day Range:
$16.16
$18.10
1-Week Range:
$14.00
$18.10
52-Week Range:
$1.06
$18.20
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
17.85 | 5.29B | 0 | -124.55M | -95.58M | -0.4393 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Jefferies Maintains Erasca(ERAS.US) With Buy Rating, Raises Target Price to $21 - Moomoo
Erasca (ERAS) Sees a 7.9% Decline, Trading at $15.66 - GuruFocus
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
Erasca (ERAS) slides 6.4% as traders digest dilution overhang and recent insider sale; no clear single-day catalyst - Quiver Quantitative
Jefferies reiterates Erasca stock Buy rating on rival trial data By Investing.com - Investing.com South Africa
ERAS Stock Slips As Form 144 Insider Sale Looms - StocksToTrade
Erasca (ERAS) Sees Significant Drop of 10.6% - GuruFocus
Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies - TipRanks
Market Review: What are Erasca Incs growth leversEarnings Risk Report & Risk Managed Trade Strategies - baoquankhu1.vn
Erasca stock surges 42% in a week: Here's what you should know - MSN
How ERAS-0015 Trial Progress and Asia Licensing Expansion Will Impact Erasca (ERAS) Investors - Sahm
Aug Drivers: How does Erasca Inc perform in inflationary periods2026 Spike Watch & Real-Time Volume Analysis Alerts - baoquankhu1.vn
ERAS Stock Price, Quote & Chart | ERASCA INC (NASDAQ:ERAS) - ChartMill
11 Most Profitable Stocks In Each Sector So Far in 2026 - Insider Monkey
What’s driving Erasca (ERAS)’s nearly 355% YTD return - MSN
What’s Driving Erasca (ERAS)’s Nearly 355% YTD Return - Insider Monkey
Exit Recap: Is Erasca Inc stock a good dividend stock2026 Macro Moves & Community Trade Idea Sharing Platform - baoquankhu1.vn
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN
Why Is Erasca, Inc. (ERAS) Stock Down Today? - Meyka
Erasca (ERAS) Among the Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
JPMorgan Chase & Co. Has $2.77 Million Stock Holdings in Erasca, Inc. $ERAS - MarketBeat
5 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
JPMorgan and Stifel Enhance Erasca’s Market Prospects with High Price Targets - timothysykes.com
Erasca CLO Ebun Garner sells $1.3m in ERAS stock By Investing.com - au.investing.com
Insider Selling: Erasca (NASDAQ:ERAS) Insider Sells 80,000 Shares of Stock - MarketBeat
Erasca CLO Ebun Garner sells $1.3m in ERAS stock - Investing.com
Erasca (ERAS) Chief Legal Officer exercises options, sells 80K shares under 10b5-1 plan - Stock Titan
Erasca (NASDAQ:ERAS) Trading 8.2% HigherHere's What Happened - MarketBeat
Erasca Inc stock hits 52-week high at $14.63 - Investing.com
Erasca Inc stock hits 52-week high at 16.41 USD By Investing.com - Investing.com South Africa
Erasca reports proposed 80,000-share sale (NASDAQ: ERAS) - Stock Titan
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - marketbeat.com
Erasca Inc stock hits 52-week high at 16.41 USD - Investing.com
ERAS Technical Analysis & Stock Price Forecast - Intellectia AI
Revenue Check: How does Erasca Inc perform in inflationary periods2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Erasca (ERAS) price target increased by 42.72% to 14.99 - MSN
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't - Yahoo Finance
Erasca (NASDAQ:ERAS) Shares Up 8.8%Should You Buy? - MarketBeat
Erasca’s Stock Surges Higher Amid Pipeline Optimism - StocksToTrade
Erasca’s HERKULES-3 Trial Reaches Completion: What Investors Should Watch in ERAS-007 - TipRanks
Erasca (ERAS) adds 13%; soars 310% YTD - MSN
Mizuho initiates Erasca (ERAS) with 'outperform' rating and $16 PT - MSN
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation - Yahoo Finance
Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - MarketScreener
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):